Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

MLA

Saatci, Ozge, et al. “Targeting LINC00152 Activates CAMP/Ca 2+ /Ferroptosis Axis and Overcomes Tamoxifen Resistance in ER+ Breast Cancer.” BioRxiv : The Preprint Server for Biology, Nov. 2023. EBSCOhost, https://doi.org/10.1101/2023.11.05.565697.

APA

Saatci, O., Alam, R., Huynh-Dam, K.-T., Isik, A., Uner, M., Belder, N., Ersan, P. G., Cetin, M., Tokat, U. M., Gedik, M. E., Bal, H., Sahin, O. S., Riazalhosseini, Y., Thieffry, D., Gautheret, D., Ogretmen, B., Aksoy, S., Uner, A., Akyol, A., & Sahin, O. (2023). Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. BioRxiv : The Preprint Server for Biology. https://doi.org/10.1101/2023.11.05.565697

Chicago

Saatci, Ozge, Rashed Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, et al. 2023. “Targeting LINC00152 Activates CAMP/Ca 2+ /Ferroptosis Axis and Overcomes Tamoxifen Resistance in ER+ Breast Cancer.” BioRxiv : The Preprint Server for Biology, November. doi:10.1101/2023.11.05.565697.